Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Soria Jean-Charles and Felip Enriqueta and Cobo Manuel and Lu Shun and Syrigos Konstantinos and Lee Ki Hyeong and Goeker Erdem and Georgoulias Vassilis and Li Wei and Isla Dolores and Guclu Salih Z and Morabito Alessandro and Min Young J and Ardizzoni Andrea and Gadgeel Shirish M and Wang Bushi and Chand Vikram K and Goss Glenwood D and Kollaborációs szervezet: LUX-Lung 8 Investigators and Somfay Attila and et al.: Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
LANCET ONCOLOGY, 16 (8). pp. 897-907. ISSN 1470-2045 (2015)

[thumbnail of 1-s2.0-S1470204515000066-main.pdf]

Text
1-s2.0-S1470204515000066-main.pdf - Published Version
Closed access: Repository staff only
Download (430kB) | Request a copy

Creators:

Soria Jean-Charles

Felip Enriqueta

Cobo Manuel

Lu Shun

Syrigos Konstantinos

Lee Ki Hyeong

Goeker Erdem

Georgoulias Vassilis

Li Wei

Isla Dolores

Guclu Salih Z

Morabito Alessandro

Min Young J

Ardizzoni Andrea

Gadgeel Shirish M

Wang Bushi

Chand Vikram K

Goss Glenwood D

Kollaborációs szervezet: LUX-Lung 8 Investigators (kollab)

Somfay Attila (kollab) MTMT

et al.

Item Type:

Journal Article

Szerzők száma:

190

Journal or Publication Title:

LANCET ONCOLOGY

Date:

2015

Volume:

Number:

Page Range:

pp. 897-907

ISSN:

1470-2045

Faculty/Unit:

Faculty of Medicine

Institution:

University of Szeged (2000-)

Language:

English

MTMT rekordazonosító:

3410569

DOI azonosító:

https://doi.org/10.1016/S1470-2045(15)00006-6

Date Deposited:

2024. Mar. 27. 14:24

Last Modified:

2024. Mar. 27. 14:24

URI:

http://publicatio.bibl.u-szeged.hu/id/eprint/29988

Web of Science® Times Cited: 335

View citing articles in Web of Science®

Actions (login required)

View Item